Read by QxMD icon Read

Hepatitis A vaccine long time efficacy

Ahmad Zia Shams, Ulrike Haug
Background: Gastrointestinal cancers account for one third of total cancer incidence and mortality in developing countries. To date, there is no systematic synthesis of evidence regarding strategies to prevent gastrointestinal cancers in developing countries. We aimed to provide a systematic overview of studies evaluating strategies for prevention or early detection of the three most common gastrointestinal cancers (gastric, liver and colorectal cancer) in developing countries. Methods: We searched MEDLINE, Web of Science and WHO Global Index Medicus databases for relevant articles published until October 2016 using combinations of the search terms "gastrointestinal", "digestive system", "gastric", "liver", "colorectal", "cancer", "prevention", "early detection" and "developing country" (including names)...
December 2017: Journal of Global Health
Nori Yoshioka, Matsuo Deguchi, Hideharu Hagiya, Masanori Kagita, Hiroko Tsukamoto, Miyuki Takao, Hisao Yoshida, Norihisa Yamamoto, Yukihiro Akeda, Yoshiko Nabetani, Ikuhiro Maeda, Yoh Hidaka, Kazunori Tomono
BACKGROUND: Health care workers (HCWs) are frequently exposed to hepatitis B virus (HBV) infection. The efficacy and safety of immunization with the hepatitis B (HB) vaccine are well recognized, but the durability of immunity and need for booster doses in those with secondary vaccine response failure remains controversial. METHODS: This was a retrospective cohort study performed at Osaka University Hospital, Japan. We examined antibodies against HB surface antigen (anti-HBs) titers annually after immunization for previously non-immunized HCWs...
2017: PloS One
Shu-Hua Hsu, An-Hsuan Chih, Yi-Chin Lee, Kuo-Chin Huang, Chyi-Feng Jan
BACKGROUND & AIM: The aim of this study was to compare the long-term efficacy of infant recombinant yeast hepatitis B vaccine (Recombinant group) and infant plasma-derived one (Plasma group) in Taiwanese freshers. METHODS: Recruited were a total of 38 377 freshmen who underwent university entrance health examinations from 2003 to 2015. Subjects were assigned into two groups-plasma type and recombinant type, according to the national neonatal hepatitis B immunization program...
December 2017: Liver International: Official Journal of the International Association for the Study of the Liver
Qi Zheng, Yichao Zheng, Jing Chen, Jia You, Yueyong Zhu, Yurui Liu, Jia Ji Jiang
Stem cells and cancer cells express a common subset of antigens called oncofetal antigens. Theoretically, vaccination with stem cells is effective at boosting the preexisting anticancer immune response. Herein we describe the efficacy of two stem cell-based vaccines in the prophylaxis and treatment of subcutaneous hepatic tumors transplanted into mice. C57BL/6j mice were vaccinated weekly with either hepatic stem cells (HSCs) or embryonic stem cells (ESCs) for three weeks, followed by a subcutaneous challenge with Hepa 1-6 cells at one week (group 1) or four weeks (group 2) after vaccination...
March 2017: Oncology Reports
H Chaouch, W Hachfi, I Fodha, O Kallala, S Saadi, A Bousaadia, F Lazrag, I Bougmiza, M Aouni, A Trabelsi, E Ben Jazia, A Letaief
Hepatitis B virus (HBV) vaccination has been part of the Expanded Programme of Immunization (EPI) in Tunisia since 1995. The aim of this study was to evaluate, for the first time, the impact of mass vaccination in Tunisia 17 years after this programme was implemented, and in parallel, assess the long-term persistence of anti-HBs antibody in the vaccinated Tunisian population. A total of 1422 students were recruited (703 vaccinated, 719 non-vaccinated). HBV seromarkers were checked. None of the students from either group had positive HBsAg...
August 18, 2016: Epidemiology and Infection
Rajeev Gautam, Yoshiaki Nishimura, Amarendra Pegu, Martha C Nason, Florian Klein, Anna Gazumyan, Jovana Golijanin, Alicia Buckler-White, Reza Sadjadpour, Keyun Wang, Zachary Mankoff, Stephen D Schmidt, Jeffrey D Lifson, John R Mascola, Michel C Nussenzweig, Malcolm A Martin
Despite the success of potent anti-retroviral drugs in controlling human immunodeficiency virus type 1 (HIV-1) infection, little progress has been made in generating an effective HIV-1 vaccine. Although passive transfer of anti-HIV-1 broadly neutralizing antibodies can protect mice or macaques against a single high-dose challenge with HIV or simian/human (SIV/HIV) chimaeric viruses (SHIVs) respectively, the long-term efficacy of a passive antibody transfer approach for HIV-1 has not been examined. Here we show, on the basis of the relatively long-term protection conferred by hepatitis A immune globulin, the efficacy of a single injection (20 mg kg(-1)) of four anti-HIV-1-neutralizing monoclonal antibodies (VRC01, VRC01-LS, 3BNC117, and 10-1074 (refs 9 - 12)) in blocking repeated weekly low-dose virus challenges of the clade B SHIVAD8...
May 5, 2016: Nature
Nahed A Makhlouf, Ahlam M Farghaly, Saad Zaky, Hebat-Alla G Rashed, Nagla H Abu Faddan, Douaa Sayed, Omnia El-Badawy, Noha Afifi, Wafaa S Hamza, Yousseria El-Sayed
Anti-HBs levels wanes with time. Many studies discussed the B cell response to HBV vaccine. However, the data about memory T cell response are limited. To evaluate the efficacy of hepatitis B vaccine via evaluating anti-HBs levels and HBsAg specific memory T-lymphocytes through descriptive study. The study was conducted in a tertiary care setting. This study included 440 vaccinated persons during infancy. Group I: 6 to less than 10 years old; Group II: 10 to less than 14 years old; Group III: 14 to less than 17 years old; Group IV: 17 years old...
September 2016: Journal of Medical Virology
Atsushi Yoshizawa, Noriyo Yamashiki, Yoshihide Ueda, Toshimi Kaido, Hideaki Okajima, Hiroyuki Marusawa, Tsutomu Chiba, Shinji Uemoto
AIM: Hepatitis B virus (HBV) reactivation after liver transplantation in HBV patients, or in HBV negative recipients of anti-hepatitis B core (HBc) positive grafts, has been prevented by prophylactic use of hepatitis B immunoglobulin (HBIG) and/or nucleoside/nucleotide analogs (NA). Vaccination against HBV is an alternative that may provide a chance to discontinue prophylaxis by producing anti-hepatitis B surface (HBs) antibodies. METHODS: We retrospectively reviewed 40 HBV positive recipients (HBV+ group) and 27 HBV negative recipients of anti-HBc positive grafts (HBV-/anti-HBc+ graft group), who were administrated double-dose hepatitis B vaccination...
May 2016: Hepatology Research: the Official Journal of the Japan Society of Hepatology
Juan Yin, Zhenhao Ji, Peifeng Liang, Qian Wu, Fuqiang Cui, Fuzhen Wang, Xiaofeng Liang, Guihua Zhuang
OBJECTIVE: To identify whether Chinese current series of three 5 μg doses for newborn hepatitis B vaccination should be replaced by the series of three 10 μg doses. METHODS: A cost-effectiveness analysis was conducted from the societal perspective based on the constructed decision tree-Markov model. Model parameters were estimated from published literatures, government documents and our surveys. The expected cost and effectiveness were compared between the 3-dose 5 μg series (the 5 μg strategy) and the 3-dose 10 μg series (the 10 μg strategy), and the incremental cost-effectiveness ratio (ICER, additional cost per quality-adjusted life-years gained) was calculated...
July 17, 2015: Vaccine
Liudmila M Tsybalova, Liudmila A Stepanova, Victor V Kuprianov, Elena A Blokhina, Marina V Potapchuk, Alexander V Korotkov, Andrey N Gorshkov, Marina A Kasyanenko, Nikolai V Ravin, Oleg I Kiselev
A long-term objective when designing influenza vaccines is to create one with broad cross-reactivity that will provide effective control over influenza, no matter which strain has caused the disease. Here we summarize the results from an investigation into the immunogenic and protective capacities inherent in variations of a recombinant protein, HBc/4M2e. This protein contains four copies of the ectodomain from the influenza virus protein M2 (M2e) fused within the immunodominant loop of the hepatitis B virus core antigen (HBc)...
June 26, 2015: Vaccine
Huey-Ling Chen, Chien-Nan Lee, Chin-Hao Chang, Yen-Hsuan Ni, Ming-Kwang Shyu, Shih-Ming Chen, Jen-Jan Hu, Hans Hsienhong Lin, Lu-Lu Zhao, Shu-Chi Mu, Ming-Wei Lai, Chyi-Long Lee, Hsien-Ming Lin, Ming-Song Tsai, Jenn-Jeih Hsu, Ding-Shinn Chen, K Arnold Chan, Mei-Hwei Chang
UNLABELLED: The efficacy and safety of maternal tenofovir disoproxil fumarate (TDF) in reducing mother-to-infant hepatitis B virus (HBV) transmissions is not clearly understood. We conducted a prospective, multicenter trial and enrolled 118 hepatitis B surface antigen (HBsAg)- and hepatitis B e antigen-positive pregnant women with HBV DNA ≥7.5 log10 IU/mL. The mothers received no medication (control group, n = 56, HBV DNA 8.22 ± 0.39 log10 IU/mL) or TDF 300 mg daily (TDF group, n = 62, HBV DNA 8...
August 2015: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
Feng Wang, Liping Shen, Fuqiang Cui, Shuang Zhang, Hui Zheng, Yong Zhang, Xiaofeng Liang, Fuzhen Wang, Shengli Bi
OBJECTIVE: To evaluate the long-term effectiveness of the plasma-derived hepatitis B vaccine that has been applied widely in five areas of China where HBV prevalence was highly endemic. METHOD: A cross-sectional investigation was conducted in 2009 at five HBV surveillance sites around China. The target study subjects of 6772 were born between 1986 and 1996 and received plasma-derived HBV vaccine. Serum samples were collected to test for HBV markers using the microparticle enzyme immunoassay...
May 28, 2015: Vaccine
Jun Zhang, Xue-Feng Zhang, Shou-Jie Huang, Ting Wu, Yue-Mei Hu, Zhong-Ze Wang, Hua Wang, Han-Min Jiang, Yi-Jun Wang, Qiang Yan, Meng Guo, Xiao-Hui Liu, Jing-Xin Li, Chang-Lin Yang, Quan Tang, Ren-Jie Jiang, Hui-Rong Pan, Yi-Min Li, J Wai-Kuo Shih, Mun-Hon Ng, Feng-Cai Zhu, Ning-Shao Xia
BACKGROUND: Hepatitis E virus (HEV) is a leading cause of acute hepatitis. The long-term efficacy of a hepatitis E vaccine needs to be determined. METHODS: In an initial efficacy study, we randomly assigned healthy adults 16 to 65 years of age to receive three doses of either a hepatitis E vaccine (vaccine group; 56,302 participants) or a hepatitis B vaccine (control group; 56,302 participants). The vaccines were administered at 0, 1, and 6 months, and the participants were followed for 19 months...
March 5, 2015: New England Journal of Medicine
Feng Wang, Jingchen Ma, Zhiyong Hao, Zhiyong Zhang, Xinjiang Zhang, Zhao Gao, Shengli Bi, Liping Shen, Feng Qiu, Yuliang Zhao
OBJECTIVE: To evaluate the long-term efficacy of Chinese hamster ovary (CHO) cell derived hepatitis B vaccine after being used for 14-16 years in country community in Hebei province in China. METHOD: A cross-sectional investigation was carried out in 3 of 7 randomly selected rural communities in Zhengding County in 2013. The children who were born between 1997 and 1999 and were vaccinated with three doses of CHO-derived hepatitis B vaccine were eligible to participate in the study...
January 3, 2015: Vaccine
Tzu-Wei Wu, Chuen-Fei Chen, Sheng-Kai Lai, Hans Hsienhong Lin, Chen-Chung Chu, Li-Yu Wang
BACKGROUND AND AIM: Hepatitis B (HB) vaccination is highly effective in reducing the risk of hepatitis B virus infection. However, breakthrough and chronic hepatitis B virus infections in vaccinated subjects raised concern about its long-term efficacy. The specific aim of the study was to explore the host genetic determinants of long-term immunological memory against HB vaccination. METHODS: We conducted a case-control study nested in a cohort of HB booster recipients who had received primary HB vaccination during infancy but failed to reside an anti-HBs titers ≥ 10 mIU/mL at the age of 15-18 years...
May 2015: Journal of Gastroenterology and Hepatology
M Takahata, S Hashino, M Onozawa, A Shigematsu, J Sugita, K Fujimoto, T Endo, T Kondo, J Tanaka, M Imamura, T Teshima
BACKGROUND: Reactivation of hepatitis B virus (HBV) infection, reverse seroconversion (RS), is a serious complication after allogeneic stem cell transplantation (alloHSCT). We previously conducted a post-transplant hepatitis B vaccine intervention trial and demonstrated the vaccine efficacy in preventing HBV-RS. This report is an update of the hepatitis B vaccine study. METHODS: In this trial, 21 patients were enrolled and received a standard 3-dose regimen of hepatitis B vaccine after discontinuation of immunosuppressants, whereas 25 transplant recipients with previous HBV infection did not receive the vaccine and served as controls...
October 2014: Transplant Infectious Disease: An Official Journal of the Transplantation Society
Sung-Jae Lee, Peter A Newman, Naihua Duan, William E Cunningham
BACKGROUND: Decade-long delays in successful implementation of Hepatitis B vaccines and ongoing obstacles in HPV vaccine roll-out suggest the importance of an implementation science approach to prepare for the effective translation of future HIV vaccines from clinical trials into routine practice. The objective of this study was to test HIV vaccine attitude items to develop reliable scales and to examine their association with HIV vaccine acceptability. METHODS: HIV vaccine attitude items were assessed as part of the L...
September 3, 2014: Vaccine
Masato Nakai, Tsukasa Seya, Misako Matsumoto, Kunitada Shimotohno, Naoya Sakamoto, Hussein H Aly
Abstract Hepatitis C virus (HCV) infection is a serious health problem worldwide that can lead to hepatocellular carcinoma or end-stage liver disease. Current treatment with pegylated interferon, ribavirin, and NS3/4A protease inhibitor would lead to a good prognosis in a large population of patients, but there is still no effective vaccine for HCV. HCV robustly infects hepatocytes in the liver. However, extrahepatic manifestations such as mixed cryoglobulinemia, a systemic immune complex-mediated disorder characterized by B-cell proliferation, which may evolve into overt B-cell non-Hodgkin's lymphoma, have been demonstrated...
August 2014: Viral Immunology
Sarah S Al Ghamdi, Hind I Fallatah, Dina M Fetyani, Jamil A Al-Mughales, Abdulhadi T Gelaidan
Chronic infection with hepatitis B virus (HBV) is a global health problem. In an attempt to control infection, worldwide HBV vaccination programs have been established. Saudi Arabia, an endemic area for HBV infection, established an HBV immunization program in 1989. This cross-sectional study evaluates the long-term protection of HBV vaccination 14-24 years after primary immunization in a high-risk group (clinical year medical students) at King Abdulaziz University Hospital in Jeddah, Saudi Arabia. All participants had complete HBV immunization at birth or in early childhood...
September 2013: Journal of Medical Virology
Lawrence G Febir, Kwaku P Asante, Dan-Bright S Dzorgbo, Kojo A Senah, Timothy S Letsa, Seth Owusu-Agyei
BACKGROUND: Malaria remains the leading cause of morbidity and mortality in sub-Saharan Africa despite tools currently available for its control. Making malaria vaccine available for routine use will be a major hallmark, but its acceptance by community members and health professionals within the health system could pose considerable challenge as has been found with the introduction of polio vaccinations in parts of West Africa. Some of these challenges may not be expected since decisions people make are many a time driven by a complex myriad of perceptions...
2013: Malaria Journal
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"